Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Allergan plc

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Allergan Announces Promotion of Wayne Swanton to Executive Vice President, Global Operations
-- Swanton to Join Allergan Executive Leadership Team Following Departure of Rob Stewart, Executive Vice President and Chief Operating Officer -- 
Tickers AGN
From PR Newswire
Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin
Allergan plc (NYSE: AGN) today announced that the CoolSculpting® treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in... 
Tickers AGN
From PR Newswire
Allergan's Migraine Leadership Recognized with Enrico Greppi Award for Excellence in Headache Research
Allergan to present award-winning study and six additional presentations at the 11th European Headache Federation Congress 
Tickers AGN
From PR Newswire
Allergan to Present at the 2017 Citi Global Healthcare Conference
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the 2017 Citi Global Healthcare Conference in New York... 
Tickers AGN
From PR Newswire
Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that David Nicholson, Allergan's Chief Research and Development Officer, and Armin Szegedi, Allergan's Vice... 
Tickers AGN
From PR Newswire
Overactive Bladder Causes Significant Burden, Regardless of Age Amongst Adults
New survey reveals impact, need for greater discussion about treatment options for condition affecting 33 million Americans(1) this Bladder Health Awareness Month 
Tickers AGN
From PR Newswire
Allergan Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia
-- Label Expansion Includes New Data Showing Long-Term VRAYLAR Therapy Delayed Time to Relapse Compared to Placebo Over the Course of up to 72 Weeks -- 
Tickers AGN
From PR Newswire
Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana,... 
Tickers AGN
From PR Newswire
Allergan to Present at Credit Suisse 26th Annual Healthcare Conference
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that William Meury, Allergan's Chief Commercial Officer, will present at the Credit Suisse 26th Annual Healthcare... 
Tickers AGN
From PR Newswire
Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion
-- Q3 2017 GAAP Continuing Operations Loss Per Share of $12.05; Q3 Non-GAAP Performance Net Income Per Share of $4.15 -- 
Tickers AGN
From PR Newswire
Allergan Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterine Fibroids at the American Society for Reproductive Medicine Annual Congress
-- Additional data from the Phase 3 VENUS II trial evaluated absence of bleeding in two courses of treatment -- 
Tickers AGN
From PR Newswire
Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)
--Ozurdex® is the first approved intravitreal injection for RVO in China-- 
Tickers AGN
From PR Newswire
Allergan Board of Directors Announces Fourth Quarter 2017 Cash Dividend and Increases Quarterly Cash Dividend for 2018
-- Underscores Allergan's Continued Strong Cash Flow, Commitment to Enhancing Shareholder Value -- 
Tickers AGN
From PR Newswire
Allergan to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids at the American Society for Reproductive Medicine 73rd Annual Congress
Allergan plc (NYSE: AGN) today announced that it has three oral presentations and a poster being presented at the American Society for Reproductive Medicine's 73rd Annual Congress (ASRM 2017) in San... 
Tickers AGN
From PR Newswire
Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decision
Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today issued an FAQ document responding to investor questions following the U.S. District Court for the Eastern District of Texas... 
Tickers AGN
From PR Newswire
U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
-- Allergan to Appeal U.S. District Court Ruling -- 
Tickers AGN
From PR Newswire
Allergan to Present New Data at the World Congress of Gastroenterology at ACG 2017
Allergan plc (NYSE: AGN) today announced that new data from its gastroenterology portfolio will be featured at the World Congress of Gastroenterology (WCOG), American College of Gastroenterology (ACG),... 
Tickers AGN
From PR Newswire
Allergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc.
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and its subsidiaries today announced that the Company has reached an agreement with InnoPharma Inc. resolving patent litigation... 
Tickers AGN
From PR Newswire
Allergan to Present Data From More Than 20 Abstracts at the 2017 Fall Clinical Dermatology Conference
Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 22 abstracts at the 2017 Fall Clinical Dermatology Conference (FCDC) in Las Vegas from October 12-15.... 
Tickers AGN
From PR Newswire
Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids
Potential First-in-Class, Oral Treatment for a Condition Affecting an Estimated 26 Million U.S. Women(1) 
Tickers AGN
From PR Newswire
Allergan to Present New Dry Eye Data at the American Academy of Optometry Meeting in Chicago
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced several Allergan-supported abstracts were selected for poster presentation at the Annual American Academy of Optometry... 
Tickers AGN
From PR Newswire
Allergan Presents Data From Seventeen Abstracts At The 2017 American Society For Dermatologic Surgery Meeting In Chicago
Allergan (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 17 Allergan-supported abstracts at the 2017 American Society for Dermatologic Surgery (ASDS) meeting... 
Tickers AGN
From PR Newswire
Allergan To Present New Data From Its Anti-Infectives Portfolio At IDWeek 2017 In San Diego
Allergan plc (NYSE: AGN) a leading global pharmaceutical company committed to improving outcomes and meeting critical needs in infectious diseases, will present new data from its anti-infectives... 
Tickers AGN
From PR Newswire
FDA Approves BOTOX® Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines Associated with Frontalis Muscle Activity In Adults
BOTOX® COSMETIC IS THE ONLY TREATMENT OF ITS KIND APPROVED BY THE FDA FOR FOREHEAD LINES, CROW'S FEET LINES AND GLABELLAR LINES1 
Tickers AGN
From PR Newswire
FDA Accepts Supplemental New Drug Application (sNDA) filing for AVYCAZ® (ceftazidime and avibactam)
- Application Seeks to Expand Label to Include an Indication and Phase 3 Data for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia... 
Tickers AGN
From PR Newswire
Allergan to Report Third Quarter 2017 Earnings and Host Conference Call and Webcast
Allergan plc (NYSE: AGN) today announced it intends to release third quarter 2017 financial results on Wednesday, November 1, 2017, prior to the open of the U.S. Financial Markets. 
Tickers AGN
From PR Newswire
ACZONE® (dapsone) Gel, 7.5% Recognized With Teen Vogue Acne Award Win
Today, Allergan plc (NYSE: AGN) is pleased to announce that ACZONE® (dapsone) Gel, 7.5%, a prescription medicine used on the skin (topical) to treat acne in people 12 years and older, has received a... 
Tickers AGN
From PR Newswire
Allergan Announces Tessa Hilado, Executive Vice President and Chief Financial Officer, to Retire from Company
Tickers AGN
From PR Newswire
Allergan Board of Directors Authorizes New $2 Billion Share Repurchase Program, Affirms Commitment to Increasing Cash Dividend Annually
- Company Reaffirms 2017 Full-Year Guidance, Including Affirming Third Quarter Revenue Guidance - 
Tickers AGN
From PR Newswire
Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia
Allergan plc (NYSE: AGN) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for... 
Tickers AGN
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.